Ticagrelor (Tablets) Instructions for Use
ATC Code
B01AC24 (Ticagrelor)
Active Substance
Ticagrelor (Rec.INN registered by WHO)
Clinical-Pharmacological Group
Antiplatelet agent
Pharmacotherapeutic Group
Antithrombotic agents; platelet aggregation inhibitor, except heparin
Pharmacological Action
Antiplatelet agent, a representative of the chemical class of cyclopentyltriazolopyrimidines. It is a selective and reversible antagonist of the P2Y12 receptor for adenosine diphosphate (ADP), capable of preventing ADP-mediated P2Y12-dependent activation and aggregation of platelets. Ticagrelor is active when administered orally and reversibly interacts with the P2Y12 ADP receptor of platelets. It does not interact with the ADP binding site itself, but its interaction with the P2Y12 ADP receptor of platelets prevents signal transduction.
Ticagrelor has an additional mechanism of action by increasing local concentrations of endogenous adenosine by inhibiting the endogenous equilibrative nucleoside transporter type 1 (ENT-1). Inhibition of ENT-1 by ticagrelor prolongs the T1/2 of adenosine and thereby increases its local extracellular concentration, enhancing the local adenosine response. Ticagrelor has no clinically significant direct effect on adenosine receptors (A1, A2A, A2B, A3) and is not metabolized to adenosine.
In patients with stable coronary artery disease on acetylsalicylic acid, Ticagrelor begins to act rapidly, as confirmed by the results of determining the mean value of platelet aggregation inhibition (PAI): 0.5 hours after taking a loading dose of 180 mg of ticagrelor, the mean PAI value is approximately 41%, the maximum PAI value of 89% is reached 2-4 hours after administration and is maintained for 2-8 hours. In 90% of patients, a final PAI value of more than 70% is achieved 2 hours after administration.
Pharmacokinetics
Ticagrelor is characterized by linear pharmacokinetics; the exposure of ticagrelor and the active metabolite (AR-C124910XX) is approximately proportional to the dose up to 1260 mg.
After oral administration, Ticagrelor is rapidly absorbed with a mean Tmax of approximately 1.5 hours. The formation of the main circulating metabolite AR-C124910XX (also active) from ticagrelor occurs rapidly with a mean Tmax of approximately 2.5 hours. After administration of 90 mg ticagrelor on an empty stomach, Cmax is 529 ng/ml, AUC is 3451 ng×h/ml. The ratio of Cmax and AUC of the metabolite to ticagrelor is 0.28 and 0.42, respectively. The mean absolute bioavailability of ticagrelor is 36%. Intake of fatty food does not affect the Cmax of ticagrelor or the AUC of the active metabolite, but leads to a 21% increase in the AUC of ticagrelor and a 22% decrease in the Cmax of the active metabolite. These small changes have minimal clinical significance; therefore, Ticagrelor can be administered regardless of food intake.
The plasma protein binding of ticagrelor and its active metabolite is high (>99%). The Vd of ticagrelor at steady state is 87.5 L.
CYP3A4 is the main isoenzyme responsible for the metabolism of ticagrelor and the formation of the active metabolite, and their interaction with other CYP3A substrates varies from activation to inhibition. Ticagrelor and the active metabolite are weak inhibitors of P-glycoprotein.
The main metabolite of ticagrelor is AR-C124910XX, which is also active, as confirmed by the results of in vitro assessment of binding to the P2Y12 ADP receptor of platelets. The systemic exposure of the active metabolite is approximately 30-40% of the exposure of ticagrelor.
The main route of elimination of ticagrelor is hepatic metabolism. After administration of radiolabeled ticagrelor, on average approximately 57.8% of radioactivity is excreted in the feces, 26.5% in the urine. The excretion of ticagrelor and the active metabolite in the urine is less than 1% of the dose. The active metabolite is mainly excreted in the bile. The mean T1/2 of ticagrelor and the active metabolite was 7 and 8.5 hours, respectively.
In elderly patients (aged 75 years and older) with acute coronary syndrome, higher exposure of ticagrelor (Cmax and AUC approximately 25% higher) and the active metabolite was observed compared to younger patients.
The mean bioavailability of the drug in Asian patients is 39% higher than in Caucasians. The bioavailability of ticagrelor is 18% lower in patients of Black race compared to Caucasian patients.
The exposure of ticagrelor and the active metabolite is approximately 20% lower, and that of its active metabolite is approximately 17% higher in patients with severe renal impairment (CrCl <30 ml/min) compared to patients with normal renal function.
Cmax and AUC of ticagrelor were 12% and 23% higher in patients with mild hepatic impairment compared to healthy volunteers.
Indications
In combination with acetylsalicylic acid: for the prevention of atherothrombotic complications in patients with acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction or ST elevation myocardial infarction), including patients treated with drug therapy and patients undergoing percutaneous coronary intervention or coronary artery bypass grafting; for the prevention of atherothrombotic complications in adult patients with a history of myocardial infarction (myocardial infarction occurred 1 year or more ago) and at high risk of atherothrombotic complications; for the prevention of atherothrombotic complications in patients aged 50 years and older with coronary artery disease and type 2 diabetes mellitus, without a history of myocardial infarction and/or stroke, who have undergone percutaneous coronary intervention.
ICD codes
| ICD-10 code | Indication |
| I20.0 | Unstable angina |
| I21 | Acute myocardial infarction |
| I26 | Pulmonary embolism |
| I74 | Embolism and thrombosis of arteries |
| I82 | Embolism and thrombosis of other veins |
| ICD-11 code | Indication |
| BA40.0 | Unstable angina |
| BA41.Z | Acute myocardial infarction, unspecified |
| BB00.Z | Thromboembolism in the pulmonary artery system, unspecified |
| BD5Z | Diseases of arteries or arterioles, unspecified |
| BD70.2 | Migratory thrombophlebitis |
| BD7Z | Diseases of veins, unspecified |
| DB98.5 | Budd-Chiari syndrome |
| BD72 | Venous thromboembolism |
| XA60H0 | Vena cava |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer orally with or without food.
For Acute Coronary Syndrome, initiate with a single 180 mg loading dose (two 90 mg tablets).
Continue with a maintenance dose of 90 mg twice daily.
Use in combination with acetylsalicylic acid, typically at a low maintenance dose of 75-100 mg once daily.
For secondary prevention post-Myocardial Infarction (occurring one year or more ago) in high-risk patients, use a maintenance dose of 60 mg twice daily.
For patients aged 50 years and older with coronary artery disease and type 2 diabetes without prior MI/stroke, use a 60 mg twice daily maintenance dose.
Treatment is recommended for up to 12 months in ACS patients; use beyond one year in post-MI patients requires caution.
If a dose is missed, take the next dose at the scheduled time; do not double the dose.
Discontinue therapy 5 days prior to elective surgery if an antiplatelet effect is not desired.
In patients receiving morphine, be aware of potentially reduced and delayed absorption of ticagrelor.
For patients with moderate hepatic impairment, use with caution; it is contraindicated in severe hepatic impairment.
Use with caution in patients with moderate to severe renal impairment.
Adverse Reactions
Immune system disorders uncommon – hypersensitivity reactions, including angioedema.
Metabolism and nutrition disorders very common – hyperuricemia; common – gout, gouty arthritis.
Psychiatric disorders uncommon – confusion.
Nervous system disorders common – headache, dizziness, syncope; uncommon – intracranial hemorrhage.
Eye disorders uncommon – eye hemorrhage.
Ear and labyrinth disorders common – vertigo; uncommon – ear bleeding.
Cardiac disorders common – arterial hypotension.
Respiratory, thoracic and mediastinal disorders very common – dyspnea; common – respiratory tract bleeding.
Gastrointestinal disorders common – gastrointestinal bleeding, diarrhea, nausea, dyspepsia, constipation; uncommon – retroperitoneal bleeding.
Skin and subcutaneous tissue disorders common – subcutaneous or cutaneous bleeding, pruritus, rash.
Musculoskeletal and connective tissue disorders uncommon – muscle hemorrhage.
Renal and urinary disorders uncommon – genital bleeding.
Reproductive system and breast disorders uncommon – genital bleeding.
Investigations common – increased blood creatinine concentration.
General disorders and administration site conditions very common – bleeding related to blood disorders (e.g., increased tendency to bruise, spontaneous hematoma, hemorrhagic diathesis); common – post-procedural bleeding, traumatic bleeding; uncommon – tumor bleeding (e.g., bladder tumor bleeding, gastric tumor bleeding, colon tumor bleeding); frequency unknown – thrombotic thrombocytopenic purpura.
Contraindications
Active pathological bleeding; history of intracranial hemorrhage; severe hepatic impairment; concomitant use of ticagrelor with potent inhibitors of CYP3A4 (e.g., ketoconazole, clarithromycin, nefazodone, ritonavir and atazanavir); age under 18 years; pregnancy, breastfeeding period; hypersensitivity to ticagrelor.
Use in Pregnancy and Lactation
The use of ticagrelor is contraindicated during pregnancy and lactation.
Use in Hepatic Impairment
Contraindicated in severe hepatic impairment.
Should be used with caution in patients with moderate hepatic impairment.
Use in Renal Impairment
Should be used with caution in patients with moderate or severe renal impairment.
Pediatric Use
Contraindicated for use under the age of 18 years.
Special Precautions
Ticagrelor should be used with caution in patients with a predisposition to bleeding (e.g., due to recent trauma, recent surgery, coagulation disorders, moderate hepatic impairment, active or recent gastrointestinal bleeding) or an increased risk of injury; in patients with concomitant therapy with drugs that increase the risk of bleeding (i.e., NSAIDs, oral anticoagulants and/or fibrinolytics) within 24 hours before taking ticagrelor; in patients with a previous ischemic stroke when therapy duration is more than 1 year (for patients with a history of myocardial infarction); in patients with moderate hepatic impairment; in patients with an increased risk of bradycardia (e.g., patients with sick sinus syndrome without a pacemaker, with second- or third-degree AV block; syncope associated with bradycardia); concomitantly with drugs that cause bradycardia; in patients with a history of bronchial asthma and/or COPD; in patients aged 75 years and older; in patients with moderate or severe renal impairment; in patients receiving therapy with angiotensin II receptor antagonists; in patients with hyperuricemia or gouty arthritis; with concomitant therapy with digoxin, potent inhibitors of glycoprotein P and moderate inhibitors of the CYP3A4 isoenzyme (e.g., verapamil and quinidine), selective serotonin reuptake inhibitors (e.g., paroxetine, sertraline and citalopram).
Antifibrinolytic therapy (aminocaproic acid or tranexamic acid) and/or therapy with recombinant factor VIIa may enhance hemostasis. After the cause of bleeding is established and it is stopped, ticagrelor therapy can be resumed.
If a patient is scheduled for surgery and the antithrombotic effect is not desired, ticagrelor therapy should be discontinued 5 days before surgery.
Patients with acute coronary syndrome with a previous ischemic stroke can take Ticagrelor for up to 12 months.
In the absence of data, therapy lasting more than 1 year should be used with caution (for patients with a history of myocardial infarction).
During the use of ticagrelor, an increase in serum creatinine content is possible, therefore, it is necessary to evaluate renal function in accordance with routine clinical practice, paying special attention to patients aged 75 years and older, patients with moderate and severe renal failure, patients receiving therapy with angiotensin II receptor antagonists.
Caution is required when using ticagrelor in patients with a history of hyperuricemia or gouty arthritis. As a preventive measure, the use of ticagrelor should be avoided in patients with hyperuricemic nephropathy.
Thrombotic thrombocytopenic purpura has been very rarely reported during the use of ticagrelor, which is a serious condition and requires immediate treatment.
In patients taking Ticagrelor, false-negative results of platelet function analysis in the diagnosis of heparin-induced thrombocytopenia were obtained. This is due to the inhibition of P2Y12 receptors of healthy donor platelets by ticagrelor when the test is performed in the patient’s serum/plasma. When interpreting the results of platelet function analysis in the diagnosis of heparin-induced thrombocytopenia, information about concomitant therapy with ticagrelor should be taken into account. Before considering the possibility of discontinuing ticagrelor, the benefit and risk of continuing therapy should be assessed, taking into account both the prothrombotic state due to heparin-induced thrombocytopenia and the increased risk of bleeding with the concomitant use of an anticoagulant and ticagrelor.
Concomitant use of ticagrelor and acetylsalicylic acid in a high maintenance dose (more than 300 mg) is not recommended.
Early discontinuation of any antiplatelet therapy, including Ticagrelor, may increase the risk of cardiovascular death, myocardial infarction, or stroke due to the underlying disease. Premature discontinuation of the drug should be avoided.
Effect on ability to drive vehicles and operate machinery
Dizziness and confusion have been reported during therapy with ticagrelor. If these phenomena occur, patients should exercise caution when driving vehicles and operating other machinery.
Drug Interactions
Concomitant use of ticagrelor with potent inhibitors of CYP3A4 (e.g., ketoconazole, clarithromycin, nefazodone, ritonavir and atazanavir) is contraindicated, as it may lead to a significant increase in ticagrelor exposure.
Concomitant use of ticagrelor with potent inducers of CYP3A4 (e.g., rifampicin, phenytoin, carbamazepine and phenobarbital) is not recommended, as their concomitant use may reduce the exposure and effectiveness of ticagrelor.
Moderate inhibitors of CYP3A4: concomitant use of diltiazem with ticagrelor increases the Cmax of ticagrelor by 69% and AUC by 2.7 times, while reducing the Cmax of the active metabolite by 38%, and AUC does not change. Ticagrelor does not affect the plasma concentrations of diltiazem. Other moderate inhibitors of CYP3A4 (e.g., amprenavir, aprepitant, erythromycin, fluconazole) can be prescribed simultaneously with ticagrelor.
According to the results of pharmacological interaction studies, concomitant use of ticagrelor with heparin, enoxaparin and acetylsalicylic acid or desmopressin does not affect the pharmacokinetics of ticagrelor, its active metabolite and ADP-dependent platelet aggregation. If there are clinical indications for the use of drugs affecting hemostasis, they should be used with caution in combination with ticagrelor.
There are no data on the concomitant use of ticagrelor with potent inhibitors of glycoprotein P (e.g., verapamil, quinidine and cyclosporine), which can increase the exposure of ticagrelor. If concomitant use cannot be avoided, then combination therapy should be carried out with caution.
A slowdown and decrease in exposure of oral P2Y12 inhibitors, including Ticagrelor and its active metabolite, was noted in patients receiving morphine therapy (reduction in ticagrelor exposure by approximately 35%). This interaction may be associated with decreased gastrointestinal motility and therefore applicable to other opioids. The clinical significance is unknown, but the data indicate the possibility of reduced efficacy of ticagrelor in patients simultaneously receiving Ticagrelor and morphine. In patients with acute coronary syndrome in whom the use of morphine cannot be delayed and rapid P2Y12 inhibition is considered critical, the use of a parenteral P2Y12 inhibitor may be considered.
Concomitant use of simvastatin at a dose above 40 mg/day with ticagrelor may lead to the development of side effects of simvastatin. Therefore, if this combination is necessary, the ratio of potential risk and benefit of therapy should be assessed. Concomitant use of ticagrelor with simvastatin and lovastatin at a dose of more than 40 mg is not recommended. Concomitant use of atorvastatin and ticagrelor increases the Cmax and AUC of atorvastatin acid metabolites by 23% and 36%, respectively. A similar increase in Cmax and AUC values is observed for all atorvastatin acid metabolites. These changes are considered clinically insignificant. Similar effects with statins metabolized by CYP3A4 cannot be excluded.
Ticagrelor is a weak inhibitor of CYP3A4. Concomitant use with CYP3A4 substrates with a narrow therapeutic index (e.g., cisapride or ergot alkaloids) is not recommended, as Ticagrelor may increase the exposure of these drugs.
When digoxin was taken concomitantly with ticagrelor, the mean Cmin of digoxin increased by approximately 30%, in some individual cases by two times. Cmax and AUC of ticagrelor and its active metabolite did not change when digoxin was used. Therefore, appropriate clinical and/or laboratory monitoring (heart rate, and if clinically indicated also ECG and blood digoxin concentrations) is recommended when ticagrelor and Pgp-dependent drugs with a narrow therapeutic index, such as digoxin, are used simultaneously.
Concomitant use of ticagrelor, levonorgestrel and ethinyl estradiol increases the exposure of ethinyl estradiol by approximately 20%, but does not affect the pharmacokinetics of levonorgestrel. No clinically significant impact on contraceptive efficacy is expected with simultaneous use of levonorgestrel, ethinyl estradiol and ticagrelor.
Due to the detection of mainly asymptomatic ventricular pauses and bradycardia, Ticagrelor should be taken with caution simultaneously with drugs that can cause bradycardia.
Concomitant use of ticagrelor with heparin, enoxaparin or desmopressin did not affect aPTT, activated clotting time and factor Xa testing, however, due to potential pharmacodynamic interaction, caution is required when used concomitantly with drugs affecting hemostasis.
Due to reports of subcutaneous hemorrhages while taking selective serotonin reuptake inhibitors (e.g., paroxetine, sertraline, and citalopram), caution is required when co-administering them with ticagrelor.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Film-coated tablets 60 mg
Film-coated tablets, 90 mg
Marketing Authorization Holder
Hetero Labs, Limited (India)
Manufactured By
Makiz-Pharma, LLC (Russia)
Or
Annora Pharma, Private Limited (India)
Dosage Forms
 |
Ticagrelor | Film-coated tablets 60 mg |
| Film-coated tablets, 90 mg |
Dosage Form, Packaging, and Composition
Film-coated tablets
| 1 tab. | |
| Ticagrelor | 60 mg |
10 pcs. – blisters (6 pcs.) – cardboard packs (60 pcs.) – By prescription
10 pcs. – blisters 10-1000 pcs. – cardboard boxes (10 pcs.) – In-Bulk
10 pcs. – contour cell packaging (6 pcs.) – cardboard packs (60 pcs.) – By prescription
60 pcs. – jars – cardboard packs (60 pcs.) – By prescription
60 pcs. – jars 15-40 pcs. – cardboard boxes (60 pcs.) – In-Bulk
60 pcs. – bottles – cardboard packs (60 pcs.) – By prescription
Film-coated tablets
| 1 tab. | |
| Ticagrelor | 90 mg |
10 pcs. – blisters (6 pcs.) – cardboard packs (60 pcs.) – By prescription
10 pcs. – blisters 10-1000 pcs. – cardboard boxes (10 pcs.) – In-Bulk
10 pcs. – contour cell packaging (6 pcs.) – cardboard packs (60 pcs.) – By prescription
60 pcs. – jars – cardboard packs (60 pcs.) – By prescription
60 pcs. – jars 15-40 pcs. – cardboard boxes (60 pcs.) – In-Bulk
60 pcs. – bottles – cardboard packs (60 pcs.) – By prescription
Film-coated tablets 60 mg: 10, 14, 30, 40, 42, 56, 120 or 168 pcs.
Film-coated tablets 90 mg: 10, 14, 30, 40, 42, 56, 120 or 168 pcs.
Marketing Authorization Holder
Aliym, JSC (Russia)
Dosage Forms
|
Ticagrelor | Film-coated tablets 60 mg: 10, 14, 30, 40, 42, 56, 120 or 168 pcs. |
| Film-coated tablets 90 mg: 10, 14, 30, 40, 42, 56, 120 or 168 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets from light pink to pink, round, biconvex; on the break – from almost white to light pink.
| 1 tab. | |
| Ticagrelor | 60 mg |
Excipients: mannitol, microcrystalline cellulose PH101, sodium starch glycolate (type A), povidone K30, magnesium stearate, iron oxide red, hypromellose 2910 (15 mPa), macrogol 3350, titanium dioxide.
10 pcs. – contour cell packaging (1, 3, 4, 12) – cardboard packs with insert.
14 pcs. – contour cell packaging (1, 3, 4, 12) – cardboard packs with insert.
28 pcs. – contour cell packaging (2, 6) – cardboard packs with insert.
Film-coated tablets from light yellow to yellow, round, biconvex; on the break – from almost white to light pink.
| 1 tab. | |
| Ticagrelor | 90 mg |
Excipients: mannitol, microcrystalline cellulose PH101, sodium starch glycolate (type A), povidone K30, magnesium stearate, iron oxide yellow, hypromellose 2910 (15 mPa), macrogol 3350, titanium dioxide.
10 pcs. – contour cell packaging (1, 3, 4, 12) – cardboard packs with insert.
14 pcs. – contour cell packaging (1, 3, 4, 12) – cardboard packs with insert.
28 pcs. – contour cell packaging (2, 6) – cardboard packs with insert.
Film-coated tablets 60 mg
Film-coated tablets, 90 mg
Marketing Authorization Holder
Atoll LLC (Russia)
Manufactured By
Ozon, LLC (Russia)
Dosage Forms
|
Ticagrelor | Film-coated tablets 60 mg |
| Film-coated tablets, 90 mg |
Dosage Form, Packaging, and Composition
Film-coated tablets
| 1 tab. | |
| Ticagrelor | 60 mg |
10 pcs. – contour cell packaging – cardboard packs (10 pcs.) – By prescription
10 pcs. – contour cell packaging (10 pcs.) – cardboard packs (100 pcs.) – By prescription
10 pcs. – contour cell packaging (12 pcs.) – cardboard packs (120 pcs.) – By prescription
10 pcs. – contour cell packaging (2 pcs.) – cardboard packs (20 pcs.) – By prescription
10 pcs. – contour cell packaging (24 pcs.) – cardboard packs (240 pcs.) – By prescription
10 pcs. – contour cell packaging (3 pcs.) – cardboard packs (30 pcs.) – By prescription
10 pcs. – contour cell packaging (4 pcs.) – cardboard packs (40 pcs.) – By prescription
10 pcs. – contour cell packaging (6 pcs.) – cardboard packs (60 pcs.) – By prescription
10 pcs. – contour cell packaging (8 pcs.) – cardboard packs (80 pcs.) – By prescription
14 pcs. – contour cell packaging – cardboard packs (14 pcs.) – By prescription
14 pcs. – contour cell packaging (10 pcs.) – cardboard packs (140 pcs.) – By prescription
14 pcs. – contour cell packaging (12 pcs.) – cardboard packs (168 pcs.) – By prescription
14 pcs. – contour cell packaging (2 pcs.) – cardboard packs (28 pcs.) – By prescription
14 pcs. – contour cell packaging (24 pcs.) – cardboard packs (336 pcs.) – By prescription
14 pcs. – contour cell packaging (3 pcs.) – cardboard packs (42 pcs.) – By prescription
14 pcs. – contour cell packaging (4 pcs.) – cardboard packs (56 pcs.) – By prescription
14 pcs. – contour cell packaging (6 pcs.) – cardboard packs (84 pcs.) – By prescription
14 pcs. – contour cell packaging (8 pcs.) – cardboard packs (112 pcs.) – By prescription
28 pcs. – contour cell packaging – cardboard packs (28 pcs.) – By prescription
28 pcs. – contour cell packaging (10 pcs.) – cardboard packs (280 pcs.) – By prescription
28 pcs. – contour cell packaging (12 pcs.) – cardboard packs (336 pcs.) – By prescription
28 pcs. – contour cell packaging (2 pcs.) – cardboard packs (56 pcs.) – By prescription
28 pcs. – contour cell packaging (24 pcs.) – cardboard packs (672 pcs.) – By prescription
28 pcs. – contour cell packaging (3 pcs.) – cardboard packs (84 pcs.) – By prescription
28 pcs. – contour cell packaging (4 pcs.) – cardboard packs (112 pcs.) – By prescription
28 pcs. – contour cell packaging (6 pcs.) – cardboard packs (168 pcs.) – By prescription
28 pcs. – contour cell packaging (8 pcs.) – cardboard packs (224 pcs.) – By prescription
7 pcs. – contour cell packaging – cardboard packs (7 pcs.) – By prescription
7 pcs. – contour cell packaging (10 pcs.) – cardboard packs (70 pcs.) – By prescription
7 pcs. – contour cell packaging (12 pcs.) – cardboard packs (84 pcs.) – By prescription
7 pcs. – contour cell packaging (2 pcs.) – cardboard packs (14 pcs.) – By prescription
7 pcs. – contour cell packaging (24 pcs.) – cardboard packs (168 pcs.) – By prescription
7 pcs. – contour cell packaging (3 pcs.) – cardboard packs (21 pcs.) – By prescription
7 pcs. – contour cell packaging (4 pcs.) – cardboard packs (28 pcs.) – By prescription
7 pcs. – contour cell packaging (6 pcs.) – cardboard packs (42 pcs.) – By prescription
7 pcs. – contour cell packaging (8 pcs.) – cardboard packs (56 pcs.) – By prescription
Film-coated tablets
| 1 tab. | |
| Ticagrelor | 90 mg |
10 pcs. – contour cell packaging – cardboard packs (10 pcs.) – By prescription
10 pcs. – contour cell packaging (10 pcs.) – cardboard packs (100 pcs.) – By prescription
10 pcs. – contour cell packaging (12 pcs.) – cardboard packs (120 pcs.) – By prescription
10 pcs. – contour cell packaging (2 pcs.) – cardboard packs (20 pcs.) – By prescription
10 pcs. – contour cell packaging (24 pcs.) – cardboard packs (240 pcs.) – By prescription
10 pcs. – contour cell packaging (3 pcs.) – cardboard packs (30 pcs.) – By prescription
10 pcs. – contour cell packaging (4 pcs.) – cardboard packs (40 pcs.) – By prescription
10 pcs. – contour cell packaging (6 pcs.) – cardboard packs (60 pcs.) – By prescription
10 pcs. – contour cell packaging (8 pcs.) – cardboard packs (80 pcs.) – By prescription
14 pcs. – contour cell packaging – cardboard packs (14 pcs.) – By prescription
14 pcs. – contour cell packaging (10 pcs.) – cardboard packs (140 pcs.) – By prescription
14 pcs. – contour cell packaging (12 pcs.) – cardboard packs (168 pcs.) – By prescription
14 pcs. – contour cell packaging (2 pcs.) – cardboard packs (28 pcs.) – By prescription
14 pcs. – contour cell packaging (24 pcs.) – cardboard packs (336 pcs.) – By prescription
14 pcs. – contour cell packaging (3 pcs.) – cardboard packs (42 pcs.) – By prescription
14 pcs. – contour cell packaging (4 pcs.) – cardboard packs (56 pcs.) – By prescription
14 pcs. – contour cell packaging (6 pcs.) – cardboard packs (84 pcs.) – By prescription
14 pcs. – contour cell packaging (8 pcs.) – cardboard packs (112 pcs.) – By prescription
28 pcs. – contour cell packaging – cardboard packs (28 pcs.) – By prescription
28 pcs. – contour cell packaging (10 pcs.) – cardboard packs (280 pcs.) – By prescription
28 pcs. – contour cell packaging (12 pcs.) – cardboard packs (336 pcs.) – By prescription
28 pcs. – contour cell packaging (2 pcs.) – cardboard packs (56 pcs.) – By prescription
28 pcs. – contour cell packaging (24 pcs.) – cardboard packs (672 pcs.) – By prescription
28 pcs. – contour cell packaging (3 pcs.) – cardboard packs (84 pcs.) – By prescription
28 pcs. – contour cell packaging (4 pcs.) – cardboard packs (112 pcs.) – By prescription
28 pcs. – contour cell packaging (6 pcs.) – cardboard packs (168 pcs.) – By prescription
28 pcs. – contour cell packaging (8 pcs.) – cardboard packs (224 pcs.) – By prescription
7 pcs. – contour cell packaging – cardboard packs (7 pcs.) – By prescription
7 pcs. – contour cell packaging (10 pcs.) – cardboard packs (70 pcs.) – By prescription
7 pcs. – contour cell packaging (12 pcs.) – cardboard packs (84 pcs.) – By prescription
7 pcs. – contour cell packaging (2 pcs.) – cardboard packs (14 pcs.) – By prescription
7 pcs. – contour cell packaging (24 pcs.) – cardboard packs (168 pcs.) – By prescription
7 pcs. – contour cell packaging (3 pcs.) – cardboard packs (21 pcs.) – By prescription
7 pcs. – contour cell packaging (4 pcs.) – cardboard packs (28 pcs.) – By prescription
7 pcs. – contour cell packaging (6 pcs.) – cardboard packs (42 pcs.) – By prescription
7 pcs. – contour cell packaging (8 pcs.) – cardboard packs (56 pcs.) – By prescription
Film-coated tablets 60 mg: 60 pcs.
Film-coated tablets 90 mg: 60 pcs.
Marketing Authorization Holder
LIFE SCIENCES OHFK, LLC (Russia)
Manufactured By
OHFK, JSC (Russia)
Dosage Forms
|
Ticagrelor | Film-coated tablets 60 mg: 60 pcs. |
| Film-coated tablets 90 mg: 60 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets from light yellow to yellow-orange; on the cross-section, the core is from almost white to light pink.
| 1 tab. | |
| Ticagrelor | 60 mg |
Excipients: mannitol, calcium hydrogen phosphate, sodium carboxymethyl starch, hyprolose, magnesium stearate, coating Opadry II 85F32410 yellow (polyvinyl alcohol, titanium dioxide, talc, macrogol 3350, iron oxide yellow (E172)).
10 pcs. – contour cell packaging (6) – cardboard packs with insert.
Film-coated tablets from light yellow to yellow-orange, round, biconvex; on the cross-section, the core is from almost white to light pink.
| 1 tab. | |
| Ticagrelor | 90 mg |
Excipients: mannitol, calcium hydrogen phosphate, sodium carboxymethyl starch, hyprolose, magnesium stearate, coating Opadry II 85F32410 yellow (polyvinyl alcohol, titanium dioxide, talc, macrogol 3350, iron oxide yellow (E172)).
10 pcs. – contour cell packaging (6) – cardboard packs with insert.
Film-coated tablets 60 mg
Film-coated tablets, 90 mg
Marketing Authorization Holder
Nizhpharm JSC (Russia)
Manufactured By
Chemopharm, LLC (Russia)
Dosage Forms
|
Ticagrelor | Film-coated tablets 60 mg |
| Film-coated tablets, 90 mg |
Dosage Form, Packaging, and Composition
Film-coated tablets
| 1 tab. | |
| Ticagrelor | 60 mg |
10 pcs. – contour cell packaging (3 pcs.) – cardboard packs (30 pcs.) – By prescription
14 pcs. – contour cell packaging (12 pcs.) – cardboard packs (168 pcs.) – By prescription
14 pcs. – contour cell packaging (4 pcs.) – cardboard packs (56 pcs.) – By prescription
Film-coated tablets
| 1 tab. | |
| Ticagrelor | 90 mg |
10 pcs. – contour cell packaging (3 pcs.) – cardboard packs (30 pcs.) – By prescription
14 pcs. – contour cell packaging (12 pcs.) – cardboard packs (168 pcs.) – By prescription
14 pcs. – contour cell packaging (4 pcs.) – cardboard packs (56 pcs.) – By prescription
Film-coated tablets 60 mg: 14, 40, 56, 168, or 180 pcs.
Film-coated tablets 90 mg: 14, 40, 56, 168, or 180 pcs.
Marketing Authorization Holder
Promomed Rus LLC (Russia)
Manufactured By
Biokhimik, JSC (Russia)
Dosage Forms
|
Ticagrelor | Film-coated tablets 60 mg: 14, 40, 56, 168, or 180 pcs. |
| Film-coated tablets 90 mg: 14, 40, 56, 168, or 180 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets from light pink to pink, oval, biconvex; on the cross-section, the core is white or white with a pinkish tint, or white with a pinkish-yellow tint, the presence of pinkish-yellow inclusions is allowed.
| 1 tab. | |
| Ticagrelor | 60 mg |
Excipients: sorbitol, prosolv (microcrystalline cellulose ≥98%, colloidal silicon dioxide ≤2%), pregelatinized starch, croscarmellose sodium, calcium carbonate, copovidone, sodium stearyl fumarate, hypromellose, titanium dioxide (E171), macrogol (polyethylene glycol), carmine red (E120), iron oxide black (E172), iron oxide yellow (E172).
7 pcs. – contour cell packaging (2) – cardboard packs.
7 pcs. – contour cell packaging (8) – cardboard packs.
14 pcs. – contour cell packaging (1) – cardboard packs.
14 pcs. – contour cell packaging (4) – cardboard packs.
14 pcs. – contour cell packaging (12) – cardboard packs.
20 pcs. – contour cell packaging (2) – cardboard packs.
40 pcs. – polyethylene jars (1) – cardboard packs.
56 pcs. – polyethylene jars (1) – cardboard packs.
168 pcs. – polyethylene jars (1) – cardboard packs.
180 pcs. – polyethylene jars (1) – cardboard packs.
Film-coated tablets from light yellow to yellow, oval, biconvex; on the cross-section, the core is white or white with a pinkish tint, or white with a pinkish-yellow tint, the presence of pinkish-yellow inclusions is allowed.
| 1 tab. | |
| Ticagrelor | 90 mg |
Excipients: sorbitol, prosolv (microcrystalline cellulose ≥98%, colloidal silicon dioxide ≤2%), pregelatinized starch, croscarmellose sodium, calcium carbonate, copovidone, sodium stearyl fumarate, hypromellose, titanium dioxide (E171), macrogol (polyethylene glycol), iron oxide yellow (E172).
7 pcs. – contour cell packaging (2) – cardboard packs.
7 pcs. – contour cell packaging (8) – cardboard packs.
14 pcs. – contour cell packaging (1) – cardboard packs.
14 pcs. – contour cell packaging (4) – cardboard packs.
14 pcs. – contour cell packaging (12) – cardboard packs.
20 pcs. – contour cell packaging (2) – cardboard packs.
40 pcs. – polyethylene jars (1) – cardboard packs.
56 pcs. – polyethylene jars (1) – cardboard packs.
168 pcs. – polyethylene jars (1) – cardboard packs.
180 pcs. – polyethylene jars (1) – cardboard packs.
Film-coated tablets 60 mg
Film-coated tablets, 90 mg
Marketing Authorization Holder
Pharmproekt, JSC (Russia)
Dosage Forms
|
Ticagrelor | Film-coated tablets 60 mg |
| Film-coated tablets, 90 mg |
Dosage Form, Packaging, and Composition
Film-coated tablets
| 1 tab. | |
| Ticagrelor | 60 mg |
10 pcs. – contour cell packs – cardboard packs (10 pcs.) – By prescription
10 pcs. – contour cell packs (10 pcs.) – cardboard packs (100 pcs.) – By prescription
10 pcs. – contour cell packs (2 pcs.) – cardboard packs (20 pcs.) – By prescription
10 pcs. – contour cell packs (3 pcs.) – cardboard packs (30 pcs.) – By prescription
10 pcs. – contour cell packs (4 pcs.) – cardboard packs (40 pcs.) – By prescription
10 pcs. – contour cell packs (5 pcs.) – cardboard packs (50 pcs.) – By prescription
10 pcs. – contour cell packs (6 pcs.) – cardboard packs (60 pcs.) – By prescription
10 pcs. – contour cell packs (7 pcs.) – cardboard packs (70 pcs.) – By prescription
10 pcs. – contour cell packs (8 pcs.) – cardboard packs (80 pcs.) – By prescription
10 pcs. – contour cell packs (9 pcs.) – cardboard packs (90 pcs.) – By prescription
14 pcs. – contour cell packs – cardboard packs (14 pcs.) – By prescription
14 pcs. – contour cell packs (10 pcs.) – cardboard packs (140 pcs.) – By prescription
14 pcs. – contour cell packs (2 pcs.) – cardboard packs (28 pcs.) – By prescription
14 pcs. – contour cell packs (3 pcs.) – cardboard packs (42 pcs.) – By prescription
14 pcs. – contour cell packs (4 pcs.) – cardboard packs (56 pcs.) – By prescription
14 pcs. – contour cell packs (5 pcs.) – cardboard packs (70 pcs.) – By prescription
14 pcs. – contour cell packs (6 pcs.) – cardboard packs (84 pcs.) – By prescription
14 pcs. – contour cell packs (7 pcs.) – cardboard packs (98 pcs.) – By prescription
14 pcs. – contour cell packs (8 pcs.) – cardboard packs (112 pcs.) – By prescription
14 pcs. – contour cell packs (9 pcs.) – cardboard packs (126 pcs.) – By prescription
14 pcs. – bottles – cardboard packs (14 pcs.) – By prescription
168 pcs. – bottles – cardboard packs (168 pcs.) – By prescription
42 pcs. – bottles – cardboard packs (42 pcs.) – By prescription
56 pcs. – bottles – cardboard packs (56 pcs.) – By prescription
7 pcs. – contour cell packs – cardboard packs (7 pcs.) – By prescription
7 pcs. – contour cell packs (10 pcs.) – cardboard packs (70 pcs.) – By prescription
7 pcs. – contour cell packs (2 pcs.) – cardboard packs (14 pcs.) – By prescription
7 pcs. – contour cell packs (3 pcs.) – cardboard packs (21 pcs.) – By prescription
7 pcs. – contour cell packs (4 pcs.) – cardboard packs (28 pcs.) – By prescription
7 pcs. – contour cell packs (5 pcs.) – cardboard packs (35 pcs.) – By prescription
7 pcs. – contour cell packs (6 pcs.) – cardboard packs (42 pcs.) – By prescription
7 pcs. – contour cell packs (7 pcs.) – cardboard packs (49 pcs.) – By prescription
7 pcs. – contour cell packs (8 pcs.) – cardboard packs (56 pcs.) – By prescription
7 pcs. – contour cell packs (9 pcs.) – cardboard packs (63 pcs.) – By prescription
Film-coated tablets
| 1 tab. | |
| Ticagrelor | 90 mg |
10 pcs. – contour cell packs – cardboard packs (10 pcs.) – By prescription
10 pcs. – contour cell packs (10 pcs.) – cardboard packs (100 pcs.) – By prescription
10 pcs. – contour cell packs (2 pcs.) – cardboard packs (20 pcs.) – By prescription
10 pcs. – contour cell packs (3 pcs.) – cardboard packs (30 pcs.) – By prescription
10 pcs. – contour cell packs (4 pcs.) – cardboard packs (40 pcs.) – By prescription
10 pcs. – contour cell packs (5 pcs.) – cardboard packs (50 pcs.) – By prescription
10 pcs. – contour cell packs (6 pcs.) – cardboard packs (60 pcs.) – By prescription
10 pcs. – contour cell packs (7 pcs.) – cardboard packs (70 pcs.) – By prescription
10 pcs. – contour cell packs (8 pcs.) – cardboard packs (80 pcs.) – By prescription
10 pcs. – contour cell packs (9 pcs.) – cardboard packs (90 pcs.) – By prescription
14 pcs. – contour cell packs – cardboard packs (14 pcs.) – By prescription
14 pcs. – contour cell packs (10 pcs.) – cardboard packs (140 pcs.) – By prescription
14 pcs. – contour cell packs (2 pcs.) – cardboard packs (28 pcs.) – By prescription
14 pcs. – contour cell packs (3 pcs.) – cardboard packs (42 pcs.) – By prescription
14 pcs. – contour cell packs (4 pcs.) – cardboard packs (56 pcs.) – By prescription
14 pcs. – contour cell packs (5 pcs.) – cardboard packs (70 pcs.) – By prescription
14 pcs. – contour cell packs (6 pcs.) – cardboard packs (84 pcs.) – By prescription
14 pcs. – contour cell packs (7 pcs.) – cardboard packs (98 pcs.) – By prescription
14 pcs. – contour cell packs (8 pcs.) – cardboard packs (112 pcs.) – By prescription
14 pcs. – contour cell packs (9 pcs.) – cardboard packs (126 pcs.) – By prescription
14 pcs. – bottles – cardboard packs (14 pcs.) – By prescription
168 pcs. – bottles – cardboard packs (168 pcs.) – By prescription
42 pcs. – bottles – cardboard packs (42 pcs.) – By prescription
56 pcs. – bottles – cardboard packs (56 pcs.) – By prescription
7 pcs. – contour cell packs – cardboard packs (7 pcs.) – By prescription
7 pcs. – contour cell packs (10 pcs.) – cardboard packs (70 pcs.) – By prescription
7 pcs. – contour cell packs (2 pcs.) – cardboard packs (14 pcs.) – By prescription
7 pcs. – contour cell packs (3 pcs.) – cardboard packs (21 pcs.) – By prescription
7 pcs. – contour cell packs (4 pcs.) – cardboard packs (28 pcs.) – By prescription
7 pcs. – contour cell packs (5 pcs.) – cardboard packs (35 pcs.) – By prescription
7 pcs. – contour cell packs (6 pcs.) – cardboard packs (42 pcs.) – By prescription
7 pcs. – contour cell packs (7 pcs.) – cardboard packs (49 pcs.) – By prescription
7 pcs. – contour cell packs (8 pcs.) – cardboard packs (56 pcs.) – By prescription
7 pcs. – contour cell packs (9 pcs.) – cardboard packs (63 pcs.) – By prescription
Film-coated tablets
| 1 tab. | |
| Ticagrelor | 90 mg |
10 pcs. – jars – cardboard packs (10 pcs.) – By prescription
10 pcs. – contour cell packs – cardboard packs (10 pcs.) – By prescription
10 pcs. – contour cell packs (10 pcs.) – cardboard packs (100 pcs.) – By prescription
10 pcs. – contour cell packs (11 pcs.) – cardboard packs (110 pcs.) – By prescription
10 pcs. – contour cell packs (12 pcs.) – cardboard packs (120 pcs.) – By prescription
10 pcs. – contour cell packs (13 pcs.) – cardboard packs (130 pcs.) – By prescription
10 pcs. – contour cell packs (2 pcs.) – cardboard packs (20 pcs.) – By prescription
10 pcs. – contour cell packs (3 pcs.) – cardboard packs (30 pcs.) – By prescription
10 pcs. – contour cell packs (4 pcs.) – cardboard packs (40 pcs.) – By prescription
10 pcs. – contour cell packs (5 pcs.) – cardboard packs (50 pcs.) – By prescription
10 pcs. – contour cell packs (6 pcs.) – cardboard packs (60 pcs.) – By prescription
10 pcs. – contour cell packs (7 pcs.) – cardboard packs (70 pcs.) – By prescription
10 pcs. – contour cell packs (8 pcs.) – cardboard packs (80 pcs.) – By prescription
10 pcs. – contour cell packs (9 pcs.) – cardboard packs (90 pcs.) – By prescription
100 pcs. – jars – cardboard packs (100 pcs.) – By prescription
112 pcs. – jars – cardboard packs (112 pcs.) – By prescription
120 pcs. – jars – cardboard packs (120 pcs.) – By prescription
126 pcs. – jars – cardboard packs (126 pcs.) – By prescription
14 pcs. – jars – cardboard packs (14 pcs.) – By prescription
14 pcs. – contour cell packs – cardboard packs (14 pcs.) – By prescription
14 pcs. – contour cell packs (10 pcs.) – cardboard packs (140 pcs.) – By prescription
14 pcs. – contour cell packs (11 pcs.) – cardboard packs (154 pcs.) – By prescription
14 pcs. – contour cell packs (12 pcs.) – cardboard packs (168 pcs.) – By prescription
14 pcs. – contour cell packs (13 pcs.) – cardboard packs (182 pcs.) – By prescription
14 pcs. – contour cell packs (2 pcs.) – cardboard packs (28 pcs.) – By prescription
14 pcs. – contour cell packs (3 pcs.) – cardboard packs (42 pcs.) – By prescription
14 pcs. – contour cell packs (4 pcs.) – cardboard packs (56 pcs.) – By prescription
14 pcs. – contour cell packs (5 pcs.) – cardboard packs (70 pcs.) – By prescription
14 pcs. – contour cell packs (6 pcs.) – cardboard packs (84 pcs.) – By prescription
14 pcs. – contour cell packs (7 pcs.) – cardboard packs (98 pcs.) – By prescription
14 pcs. – contour cell packs (8 pcs.) – cardboard packs (112 pcs.) – By prescription
14 pcs. – contour cell packs (9 pcs.) – cardboard packs (126 pcs.) – By prescription
140 pcs. – jars – cardboard packs (140 pcs.) – By prescription
154 pcs. – jars – cardboard packs (154 pcs.) – By prescription
160 pcs. – jars – cardboard packs (160 pcs.) – By prescription
168 pcs. – jars – cardboard packs (168 pcs.) – By prescription
170 pcs. – jars – cardboard packs (170 pcs.) – By prescription
180 pcs. – jars – cardboard packs (180 pcs.) – By prescription
182 pcs. – jars – cardboard packs (182 pcs.) – By prescription
20 pcs. – jars – cardboard packs (20 pcs.) – By prescription
28 pcs. – jars – cardboard packs (28 pcs.) – By prescription
30 pcs. – jars – cardboard packs (30 pcs.) – By prescription
40 pcs. – jars – cardboard packs (40 pcs.) – By prescription
42 pcs. – jars – cardboard packs (42 pcs.) – By prescription
50 pcs. – jars – cardboard packs (50 pcs.) – By prescription
56 pcs. – jars – cardboard packs (56 pcs.) – By prescription
60 pcs. – jars – cardboard packs (60 pcs.) – By prescription
7 pcs. – contour cell packs – cardboard packs (7 pcs.) – By prescription
7 pcs. – contour cell packs (10 pcs.) – cardboard packs (70 pcs.) – By prescription
7 pcs. – contour cell packs (11 pcs.) – cardboard packs (77 pcs.) – By prescription
7 pcs. – contour cell packs (12 pcs.) – cardboard packs (84 pcs.) – By prescription
7 pcs. – contour cell packs (13 pcs.) – cardboard packs (91 pcs.) – By prescription
7 pcs. – contour cell packs (2 pcs.) – cardboard packs (14 pcs.) – By prescription
7 pcs. – contour cell packs (3 pcs.) – cardboard packs (21 pcs.) – By prescription
7 pcs. – contour cell packs (4 pcs.) – cardboard packs (28 pcs.) – By prescription
7 pcs. – contour cell packs (5 pcs.) – cardboard packs (35 pcs.) – By prescription
7 pcs. – contour cell packs (6 pcs.) – cardboard packs (42 pcs.) – By prescription
7 pcs. – contour cell packs (7 pcs.) – cardboard packs (49 pcs.) – By prescription
7 pcs. – contour cell packs (8 pcs.) – cardboard packs (56 pcs.) – By prescription
7 pcs. – contour cell packs (9 pcs.) – cardboard packs (63 pcs.) – By prescription
70 pcs. – jars – cardboard packs (70 pcs.) – By prescription
80 pcs. – jars – cardboard packs (80 pcs.) – By prescription
84 pcs. – jars – cardboard packs (84 pcs.) – By prescription
90 pcs. – jars – cardboard packs (90 pcs.) – By prescription
98 pcs. – jars – cardboard packs (98 pcs.) – By prescription
Film-coated tablets 60 mg: 56 or 168 pcs.
Film-coated tablets 90 mg: 56 or 168 pcs.
Marketing Authorization Holder
Sandoz CJS (Russia)
Manufactured By
Pharos Mt, Ltd. (Malta)
Dosage Forms
|
Ticagrelor Sandoz® | Film-coated tablets 60 mg: 56 or 168 pcs. |
| Film-coated tablets 90 mg: 56 or 168 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets round, biconvex, pink in color, marked “60” on one side and smooth on the other side.
| 1 tab. | |
| Ticagrelor | 60 mg |
Excipients: mannitol (E421), calcium hydrogen phosphate dihydrate, corn starch, pregelatinized starch (corn), talc (E553b), sodium stearyl fumarate, polyvinyl alcohol (E1203), titanium dioxide (E171), glyceryl moncaprylate, sodium lauryl sulfate, iron oxide red dye (E172), iron oxide black dye (E172).
14 pcs. – blisters (4) – cardboard packs.
14 pcs. – blisters (12) – cardboard packs.
Film-coated tablets round, biconvex, yellow in color, marked “90” on one side and smooth on the other side.
| 1 tab. | |
| Ticagrelor | 90 mg |
Excipients: mannitol (E421), calcium hydrogen phosphate dihydrate, corn starch, pregelatinized starch (corn), talc (E553b), sodium stearyl fumarate, polyvinyl alcohol (E1203), titanium dioxide (E171), glyceryl moncaprylate, sodium lauryl sulfate, iron oxide yellow dye (E172).
14 pcs. – blisters (4) – cardboard packs.
14 pcs. – blisters (12) – cardboard packs.
Film-coated tablets 60 mg
Film-coated tablets, 90 mg
Marketing Authorization Holder
AmantisMed, LLC (Republic of Belarus)
Dosage Forms
|
Ticagrelor-AM | Film-coated tablets 60 mg |
| Film-coated tablets, 90 mg |
Dosage Form, Packaging, and Composition
Film-coated tablets
| 1 tab. | |
| Ticagrelor | 60 mg |
10 pcs. – contour cell packs (17 pcs.) – cardboard packs (170 pcs.) – By prescription
10 pcs. – contour cell packs (3 pcs.) – cardboard packs (30 pcs.) – By prescription
10 pcs. – contour cell packs (6 pcs.) – cardboard packs (60 pcs.) – By prescription
Film-coated tablets
| 1 tab. | |
| Ticagrelor | 90 mg |
10 pcs. – contour cell packs (17 pcs.) – cardboard packs (170 pcs.) – By prescription
10 pcs. – contour cell packs (3 pcs.) – cardboard packs (30 pcs.) – By prescription
10 pcs. – contour cell packs (6 pcs.) – cardboard packs (60 pcs.) – By prescription
Film-coated tablets 60 mg
Film-coated tablets, 90 mg
Marketing Authorization Holder
Amedart LLC (Russia)
Dosage Forms
|
Ticagrelor-Amedart | Film-coated tablets 60 mg |
| Film-coated tablets, 90 mg |
Dosage Form, Packaging, and Composition
Film-coated tablets
| 1 tab. | |
| Ticagrelor | 60 mg |
10 pcs. – blisters – cardboard packs (10 pcs.) – By prescription
10 pcs. – blisters (2 pcs.) – cardboard packs (20 pcs.) – By prescription
10 pcs. – blisters (3 pcs.) – cardboard packs (30 pcs.) – By prescription
10 pcs. – blisters (4 pcs.) – cardboard packs (40 pcs.) – By prescription
10 pcs. – blisters (6 pcs.) – cardboard packs (60 pcs.) – By prescription
14 pcs. – jars – cardboard packs (14 pcs.) – By prescription
14 pcs. – blisters – cardboard packs (14 pcs.) – By prescription
14 pcs. – blisters (2 pcs.) – cardboard packs (28 pcs.) – By prescription
14 pcs. – blisters (3 pcs.) – cardboard packs (42 pcs.) – By prescription
14 pcs. – blisters (4 pcs.) – cardboard packs (56 pcs.) – By prescription
14 pcs. – blisters (6 pcs.) – cardboard packs (84 pcs.) – By prescription
56 pcs. – jars – cardboard packs (56 pcs.) – By prescription
Film-coated tablets
| 1 tab. | |
| Ticagrelor | 90 mg |
10 pcs. – blisters – cardboard packs (10 pcs.) – By prescription
10 pcs. – blisters (2 pcs.) – cardboard packs (20 pcs.) – By prescription
10 pcs. – blisters (3 pcs.) – cardboard packs (30 pcs.) – By prescription
10 pcs. – blisters (4 pcs.) – cardboard packs (40 pcs.) – By prescription
10 pcs. – blisters (6 pcs.) – cardboard packs (60 pcs.) – By prescription
14 pcs. – jars – cardboard packs (14 pcs.) – By prescription
14 pcs. – blisters – cardboard packs (14 pcs.) – By prescription
14 pcs. – blisters (2 pcs.) – cardboard packs (28 pcs.) – By prescription
14 pcs. – blisters (3 pcs.) – cardboard packs (42 pcs.) – By prescription
14 pcs. – blisters (4 pcs.) – cardboard packs (56 pcs.) – By prescription
14 pcs. – blisters (6 pcs.) – cardboard packs (84 pcs.) – By prescription
56 pcs. – jars – cardboard packs (56 pcs.) – By prescription
![Ticagrelor [Tablets] 1](https://www.medixlife.com/wp-content/uploads/Medixlife_favi_512.png "Ticagrelor [Tablets] 2")